Literature DB >> 9498466

Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection.

F Y Lin1, J D Clemens, P H Azimi, J A Regan, L E Weisman, J B Philips, G G Rhoads, P Clark, R A Brenner, P Ferrieri.   

Abstract

The distribution of serotypes of group B streptococci (GBS) isolated from 67 infants with early-onset sepsis are described. Case-infants were assembled from 13 hospitals across the United States from 15 July 1995 to 5 February 1997 through prospective active surveillance. The distribution of GBS serotypes was Ia, 40%; Ib, 9%; II, 6%; III, 27%; V, 15%; and nontypeable, 3%. Type V occurred more frequently in the northeast region (New York and New Jersey) than in other regions (29% vs. 9%, P = .06). Conversely, type III occurred significantly less frequently in the northeast region than other regions (10% vs. 35%, P = .04). GBS types Ia, III, and V accounted for 82% of the isolates. This report supports previous observations about the emergence of GBS type V, but our data caution that conclusions about serotype distributions based on one geographic location or on a small number of patients may not be generally applicable. Continued monitoring seems necessary for the design of a GBS vaccine.

Entities:  

Mesh:

Year:  1998        PMID: 9498466     DOI: 10.1086/517810

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Inhibition enzyme-linked immunosorbent assay for serotyping of group B streptococcal isolates.

Authors:  G Arakere; A E Flores; P Ferrieri; C E Frasch
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

2.  High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan.

Authors:  P R Hsueh; L J Teng; L N Lee; S W Ho; P C Yang; K T Luh
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci.

Authors:  Daniel J Diekema; Janet I Andrews; Holly Huynh; Paul R Rhomberg; Stella R Doktor; Jill Beyer; Virginia D Shortridge; Robert K Flamm; Ronald N Jones; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

4.  Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.

Authors:  C Gravekamp; D L Kasper; L C Paoletti; L C Madoff
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

5.  Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.

Authors:  Ravin Seepersaud; Sean B Hanniffy; Peter Mayne; Phil Sizer; Richard Le Page; Jerry M Wells
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

6.  Phylogenetic lineages of invasive and colonizing strains of serotype III group B Streptococci from neonates: a multicenter prospective study.

Authors:  Feng-Ying C Lin; April Whiting; Elisabeth Adderson; Shinji Takahashi; Diane Marie Dunn; Robert Weiss; Parvin H Azimi; Joseph B Philips; Leonard E Weisman; Joan Regan; Penny Clark; George G Rhoads; Carl E Frasch; James Troendle; Patricia Moyer; John F Bohnsack
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

7.  Population structure of invasive and colonizing strains of Streptococcus agalactiae from neonates of six U.S. Academic Centers from 1995 to 1999.

Authors:  John F Bohnsack; April Whiting; Marcelo Gottschalk; Diane Marie Dunn; Robert Weiss; Parvin H Azimi; Joseph B Philips; Leonard E Weisman; George G Rhoads; Feng-Ying C Lin
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

8.  Identification of group B streptococcal Sip protein, which elicits cross-protective immunity.

Authors:  B R Brodeur; M Boyer; I Charlebois; J Hamel; F Couture; C R Rioux; D Martin
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

9.  Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae.

Authors:  Herve Tettelin; Vega Masignani; Michael J Cieslewicz; Jonathan A Eisen; Scott Peterson; Michael R Wessels; Ian T Paulsen; Karen E Nelson; Immaculada Margarit; Timothy D Read; Lawrence C Madoff; Alex M Wolf; Maureen J Beanan; Lauren M Brinkac; Sean C Daugherty; Robert T DeBoy; A Scott Durkin; James F Kolonay; Ramana Madupu; Matthew R Lewis; Diana Radune; Nadezhda B Fedorova; David Scanlan; Hoda Khouri; Stephanie Mulligan; Heather A Carty; Robin T Cline; Susan E Van Aken; John Gill; Maria Scarselli; Marirosa Mora; Emilia T Iacobini; Cecilia Brettoni; Giuliano Galli; Massimo Mariani; Filippo Vegni; Domenico Maione; Daniela Rinaudo; Rino Rappuoli; John L Telford; Dennis L Kasper; Guido Grandi; Claire M Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-28       Impact factor: 11.205

10.  Adherence to, invasion by, and cytokine production in response to serotype VIII group B Streptococci.

Authors:  Hiroshige Mikamo; Atul K Johri; Lawrence C Paoletti; Lawrence C Madoff; Andrew B Onderdonk
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.